Vitamin D Insufficiency and Deficiency in Chronic Kidney Disease (CKD) Patients in Singapore

Prevalence of Vitamin D Insufficiency and Deficiency in Chronic Kidney Disease Patients in Singapore

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01102179

Enrollment

196

Registered

2010-04-13

Start date

2010-04-30

Completion date

2014-07-31

Last updated

2014-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Predialysis, Stage 2-5 Chronic Kidney Disease

Brief summary

Vitamin D insufficiency and deficiency is common in chronic kidney disease (CKD) patients and is associated with elevated parathyroid hormone (PTH) concentration and mineral and bone disorder (MBD). There is also increasing evidence to show that these abnormalities increase cardiovascular morbidity and mortality in CKD patients. There is a need for early identification of vitamin D insufficiency/deficiency in CKD patients to prevent its long-term complications. However, the vitamin D status of CKD patients in Singapore has not been well described. The purpose of this study is to assess the vitamin D status of predialysis CKD patients in a tertiary academic teaching hospital in Singapore, and its association with parameters for MBD. Predialysis patients from the outpatient renal clinic at the National University Hospital (NUH) will be recruited into this study. Blood samples from the patients will be collected after an overnight fast to determine their serum 25(OH)D, creatinine, phosphorus, calcium, albumin and i-PTH concentrations. These parameters will be compared among patients in various stages of CKD.

Interventions

None listed

Study design

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male or female 21 years of age or older * CKD stage 2 to 5 (who are not on dialysis): CKD stage 2: eGFR 60-89ml/min/1.73m2, stage 3: eGFR 30-59ml/min/1.73m2, stage 4: eGFR 15-29 ml/min/1.73m2, stage 5 eGFR \<15 ml/min/1.73m2) * Not receiving over-the-counter or prescription vitamin D therapy * On a stable dose of phosphate binder (if any) for at least 1 month prior to the study

Exclusion criteria

* History of liver and chronic inflammatory diseases, primary hyperparathyroidism and malignancies * Use of corticosteroids, anticonvulsants or vitamin D compounds * Use of an investigational agent within 30 days of study entry

Design outcomes

Primary

Measure	Time frame	Description
Vitamin D 25(OH)D levels	baseline	Vitamin D levels are only measured at one time point i.e. at baseline

Countries

Singapore

Outcome results